查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1451738

2024-2032 年按类型（1 型、2 型等）、诊断和治疗（诊断、治疗）、最终用户（医院、家庭护理、专科诊所等）和地区分類的法布瑞氏症市场报告

Fabry Disease Market Report by Type (Type 1, Type 2, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Homecare, Specialty Clinics, and Others), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3个工作天内

价格

2023年，全球法布瑞氏症市场规模达到20亿美元。展望未来， IMARC Group预计到2032年市场规模将达到36亿美元，2024-2032年复合年增长率（CAGR）为6.34%。患有法布瑞氏症的患者数量不断增加，以及对遗传和酵素替代疗法等有效新疗法的需求不断增加，是推动市场发展的一些关键因素。

法布瑞氏症或α 半乳糖苷酶A 缺乏症是一种严重的X 连锁溶小体遗传性疾病，由缺乏代谢各种脂质储存和脂肪样成分（包括油、脂肪酸和蜡）所需的酶引起。如果不及时诊断或治疗，可能会导致血管和组织阻塞、进行性肾衰竭、神经损伤，甚至中风。目前，法布瑞氏症可以在酵素替代疗法（ERT）和辅助疗法的支持下进行治疗。除此之外，还可以透过基因、血液、肠外检查进一步确诊，抑制肾臟、心臟问题的发生。这些方法可防止发生一级和二级併发症的风险，并纠正潜在的酵素缺乏症。因此，医院和专科诊所广泛利用各种程序来及时诊断和有效治疗法布瑞氏症。

法布瑞氏症市场趋势：

患有法布瑞氏症的患者数量不断增加，以及对精确有效疗法的需求不断增加，例如遗传、酵素替代底物减少和稳定个体免受疾病影响的伴侣治疗，是推动市场成长的主要动力。与此一致的是，对用于疾病治疗的口服药物和胶囊的需求不断增长是另一个增长诱导因素。此外，监管机构为投资医疗保健产业以设计突破性疾病治疗方案所采取的有利措施正在支持市场成长。此外，重大技术进步，例如用于诊断和治疗法布瑞氏症的远距医疗解决方案和家庭护理设置的引入，有利于市场成长。人们对该疾病的认识不断提高，也大大推动了市场的发展。医生和个人对早期诊断和多种预防措施的可用性的认识不断增强，这有助于市场的成长。老年人口不断增加，容易患任何慢性病，这是推动市场成长的另一个因素。其他因素，例如医疗保健基础设施的显着改善、对遗传疾病疗法进步的更加关注以及扩大治疗和药物组合的持续研发（R＆D）活动，正在为市场创造积极的前景。

本报告回答的关键问题：

  • 迄今为止，全球法布瑞氏症市场表现如何，未来几年将如何表现？
  • 全球法布瑞氏症市场的驱动因素、限制因素和机会是什么？
  • 主要区域市场有哪些？
  • 哪些国家代表了最具吸引力的法布瑞氏症市场？
  • 依类型划分市场是怎么样的？
  • 基于诊断和治疗的市场区隔是什么？
  • 基于最终用户的市场区隔是什么？
  • 全球法布瑞氏症市场的竞争结构如何？
  • 全球法布瑞氏症市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球法布瑞氏症市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：按类型

  • 类型1
    • 市场走向
    • 市场预测
  • 2型
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：透过诊断与治疗

  • 诊断
    • 市场走向
    • 关键环节
      • 验血
      • 基因检测
      • 肠外试验
      • 其他的
    • 市场预测
  • 治疗
    • 市场走向
    • 关键环节
      • 酵素替代疗法
      • 口腔治疗
      • 辅助治疗
      • 其他的
    • 市场预测

第 8 章：市场区隔：依最终用户

  • 医院
    • 市场走向
    • 市场预测
  • 居家护理
    • 市场走向
    • 市场预测
  • 专科诊所
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：驱动因素、限制与机会

  • 概述
  • 司机
  • 限制
  • 机会

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Amicus Therapeutics
    • Freeline
    • Idorsia Pharmaceuticals Ltd
    • JCR Pharmaceuticals Co. Ltd
    • Protalix BioTherapeutics
    • Sangamo Therapeutics Inc.
Product Code: SR112024A6668

The global fabry disease market size reached US$ 2.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.34% during 2024-2032. The increasing number of patients suffering from fabry disease and the escalating need for effective novel therapies, such as genetic and enzyme replacement therapy, represent some of the key factors driving the market.

Fabry disease, or alpha galactosidase-A deficiency, represents a severe x-linked lysosomal inherited disorder that is caused by the lack of enzymes that are required to metabolize various lipid storage and fat-like components, including oils, fatty acids, and waxes. If left undiagnosed or untreated, it might result in clogging of blood vessels and tissue, progressive kidney failures, nerve damage, and even strokes. Currently, fabry disease can be treated with the support of enzyme replacement therapies (ERT) and adjunct therapy. Apart from this, it can be further diagnosed through genetic, blood, and parenteral examinations to inhibit the occurrence of kidney and heart problems. These approaches prevent the risk of developing first and second-level complications and correct underlying enzyme deficiency. Consequently, hospitals and specialty clinics widely utilize various procedures for the timely diagnosis and effective treatment of the Fabry disease.

Fabry Disease Market Trends:

The increasing number of patients suffering from fabry disease and the escalating need for precise and effective therapies, such as genetic, enzyme replacement substrate reduction, and chaperone treatments to stabilize individuals from suffering disease, are primarily driving the market growth. In line with this, the rising demand for orally administered medications and capsule for disease treatment is acting as another growth-inducing factor. Additionally, the favorable initiatives being undertaken by regulatory bodies to invest in the healthcare sector for the designing of breakthrough disease treatment options are supporting the market growth. Moreover, significant technological advancements, such as the introduction of telemedicine solutions and home care settings for the diagnosis and treatment of Fabry disease, are favoring the market growth. The market is also significantly driven by the rising awareness regarding the disease. There is an increasing consciousness regarding the availability of early-stage diagnosis and multiple preventive measures amongst physicians and individuals, which is contributing to the market growth. The steadily increasing geriatric population, which is susceptible to any kind of chronic ailments, is another factor contributing to the market growth. Other factors, such as significant improvements in the healthcare infrastructure, an enhanced focus on the advancement of the genetic disease therapies, and continuous research and development (R&D) activities to expand treatment and medication portfolios, are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global fabry disease market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on type, diagnosis and treatment, and end user.

Type Insights:

Type 1

Type 2

Others

The report has also provided a detailed breakup and analysis of the fabry disease market based on the type. This includes Type 1, Type 2 and others.

Diagnosis and Treatment Insights:

Diagnosis

Blood Test

Genetic Test

Parenteral Test

Others

Treatment

Enzyme Replacement Therapy

Oral Therapy

Adjunct Therapy

Others

A detailed breakup and analysis of the fabry disease market based on the diagnosis and treatment has also been provided in the report. This includes diagnosis (blood test, genetic test, parental test, and others) and treatment (enzyme replacement therapy, oral therapy, adjunct therapy, and others).

End User Insights:

Hospitals

Homecare

Specialty Clinics

Others

A detailed breakup and analysis of the fabry disease market based on the end user has also been provided in the report. This includes hospitals, homecare, specialty clinics and others. According to the report, specialty clinics accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for Fabry disease. Some of the factors driving the North America fabry disease market included the increasing prevalence of fabry disease and the ongoing approvals of advanced therapeutics by regional governments for the disorder treatment.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global fabry disease market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amicus Therapeutics, Freeline, Idorsia Pharmaceuticals Ltd, JCR Pharmaceuticals Co. Ltd, Protalix BioTherapeutics, Sangamo Therapeutics Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global fabry disease market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global fabry disease market?
  • What are the key regional markets?
  • Which countries represent the most attractive fabry disease markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the diagnosis and treatment?
  • What is the breakup of the market based on the end user?
  • What is the competitive structure of the global fabry disease market?
  • Who are the key players/companies in the global fabry disease market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Fabry Disease Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Type 1
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Type 2
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Diagnosis & Treatment

  • 7.1 Diagnosis
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Blood Test
      • 7.1.2.2 Genetic Test
      • 7.1.2.3 Parenteral Test
      • 7.1.2.4 Others
    • 7.1.3 Market Forecast
  • 7.2 Treatment
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Enzyme Replacement Therapy
      • 7.2.2.2 Oral Therapy
      • 7.2.2.3 Adjunct Therapy
      • 7.2.2.4 Others
    • 7.2.3 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Homecare
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Specialty Clinics
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amicus Therapeutics
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Freeline
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Idorsia Pharmaceuticals Ltd
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 JCR Pharmaceuticals Co. Ltd
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Protalix BioTherapeutics
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Sangamo Therapeutics Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Fabry Disease Market: Major Drivers and Challenges
  • Figure 2: Global: Fabry Disease Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Fabry Disease Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Fabry Disease Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Fabry Disease Market: Breakup by Diagnosis & Treatment (in %), 2023
  • Figure 6: Global: Fabry Disease Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Fabry Disease Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Fabry Disease (Type 1) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Fabry Disease (Type 1) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Fabry Disease (Type 2) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Fabry Disease (Type 2) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Fabry Disease (Other Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Fabry Disease (Other Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Fabry Disease (Diagnosis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Fabry Disease (Diagnosis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Fabry Disease (Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Fabry Disease (Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Fabry Disease (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Fabry Disease (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Fabry Disease (Homecare) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Fabry Disease (Homecare) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Fabry Disease (Specialty Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Fabry Disease (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Fabry Disease (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Fabry Disease (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: North America: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: North America: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: United States: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: United States: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Canada: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Canada: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Asia-Pacific: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Asia-Pacific: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: China: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: China: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Japan: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Japan: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: India: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: India: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: South Korea: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: South Korea: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Australia: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Australia: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Indonesia: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Indonesia: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Others: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Others: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Europe: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Europe: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Germany: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Germany: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: France: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: France: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United Kingdom: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United Kingdom: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Italy: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Italy: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Spain: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Spain: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Russia: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Russia: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Latin America: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Latin America: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Brazil: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Brazil: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Mexico: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Mexico: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Middle East and Africa: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Middle East and Africa: Fabry Disease Market: Breakup by Country (in %), 2023
  • Figure 74: Middle East and Africa: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Global: Fabry Disease Industry: Drivers, Restraints, and Opportunities
  • Figure 76: Global: Fabry Disease Industry: Value Chain Analysis
  • Figure 77: Global: Fabry Disease Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Fabry Disease Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Fabry Disease Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Fabry Disease Market Forecast: Breakup by Diagnosis & Treatment (in Million US$), 2024-2032
  • Table 4: Global: Fabry Disease Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Fabry Disease Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Fabry Disease Market: Competitive Structure
  • Table 7: Global: Fabry Disease Market: Key Players